Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

  • In development
  • GID-TA11477
  • Expected publication date: TBC

The appraisal has been delayed following a request from the company.

Suggested remit: To appraise the clinical and cost effectiveness of Semaglutide within its marketing authorisation for treating liver fibrosis.